tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2022 Jun 7;9(7)
fac283.
doi: 10.1093/ofid/ofac283. eCollection 2022 Jul.
Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
Eloy E Ordaya[SUP] 1 [/SUP], Elena Beam[SUP] 1 [/SUP], Joseph D Yao[SUP] 2 [/SUP], Raymund R Razonable[SUP] 1 [/SUP], Paschalis Vergidis[SUP] 1 [/SUP]
Affiliations
Abstract
Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.
Keywords: COVID-19; immunocompromised hosts; monoclonal antibodies; transplant infectious diseases.
. 2022 Jun 7;9(7)
fac283.doi: 10.1093/ofid/ofac283. eCollection 2022 Jul.
Characterization of Early-Onset Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Immunocompromised Patients Who Received Tixagevimab-Cilgavimab Prophylaxis
Eloy E Ordaya[SUP] 1 [/SUP], Elena Beam[SUP] 1 [/SUP], Joseph D Yao[SUP] 2 [/SUP], Raymund R Razonable[SUP] 1 [/SUP], Paschalis Vergidis[SUP] 1 [/SUP]
Affiliations
- PMID: 35859990
- PMCID: PMC9214166
- DOI: 10.1093/ofid/ofac283
Abstract
Tixagevimab-cilgavimab is authorized for preexposure prophylaxis against coronavirus disease 2019 (COVID-19) in immunocompromised hosts. Herein, we report the clinical characteristics of 8 patients who developed COVID-19 soon after receiving tixagevimab-cilgavimab. This study emphasizes the need to maintain additional measures to prevent COVID-19 during periods of high severe acute respiratory syndrome coronavirus 2 transmission.
Keywords: COVID-19; immunocompromised hosts; monoclonal antibodies; transplant infectious diseases.